Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Main Article Content

Michael Migden
Danny Rischin
Medha Sasane
Vera Mastey
Anna Pavlick
Chrysalyne Schmults
Zhen Chen
Alexander Guminski
Axel Hauschild
Denise Bury
Stacie Hudgens
Anne Lynn Chang
Guilherme Rabinowits
Sherrif Ibrahim
Matthew Fury
Israel Lowy
Siyu Li
Chieh-I Chen

Keywords

Basal Cell Carcinoma, BCC, Biologic, Cemiplimab, Quality of Life, Pain

Abstract

Abstract not available.

References

1. Mills KC et al. Arch Dermatol. 2012;148:1422–1423.

2. Ahmed SR et al. Expert Rev Clin Pharmacol. 2019;12:947–951.

3. Migden MR et al. N Engl J Med. 2018;379:341–351.

4. Rischin D et al. Ann Oncol. 2019;30(suppl):536–537.

5. Migden MR et al. J Clin Oncol. 2019;37(suppl):6015.

6. Migden MR et al. Lancet Oncol. 2020;21:294–305.

7. Eisenhauer et al. Eur J Cancer. 2009;45:228–247.

8. Aaronson NK et al. J Natl Cancer Inst. 1993;85:365–376.

9. Osoba D et al. J Clin Oncol. 1998;16:139–144.

Most read articles by the same author(s)

1 2 3 > >>